| Symbol | NAMS |
|---|---|
| Name | NEWAMSTERDAM PHARMA CO N.V. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Pharmaceutical Preparations |
| Address | GOOIMEER 2-35, NARRDEN, P7 1411 DC |
| Telephone | 35 206 2971 |
| Fax | — |
| — | |
| Website | https://www.newamsterdampharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001936258 |
| Description | NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. Additional info from NASDAQ: |
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
Read moreNewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
Read moreNew Form 144/A - NewAmsterdam Pharma Co N.V. <b>Filed:</b> 2026-08-25 <b>AccNo:</b> 0001968582-26-000878 <b>Size:</b> 5 KB
Read more📋 Kastelein Johannes Jacob Pieter (Affiliate) plans to sell 125K shares of NewAmsterdam Pharma Company N.V. (at $27.87 each, total $3.5M) Filed: Aug 24, 2026 | ID: 000868
Read more(99% Neutral) NEWAMSTERDAM PHARMA CO N.V. (NAMSW) Announces New Board Appointment
Read moreNew Form 8-K/A - NewAmsterdam Pharma Co N.V. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352233 <b>Size:</b> 213 KB <br />Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read moreNew Form 3 - NewAmsterdam Pharma Co N.V. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352209 <b>Size:</b> 17 KB
Read moreNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more(90% Positive) NEWAMSTERDAM PHARMA CO N.V. (NAMS) Announces Enrollment Update for expected Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read more